Poe Hein Eer and her colleagues set out to investigate.

In our latest study, we profiled 576 tumors from patients to see, and these are actually from 13 different neuroendocrine tumor types.

and different neuroendocrine carcinoma types as well.

So there are 13 in category in total, and there are 576 tumor in this study.

And then so our pathologist, Dr. Andrew Bellisi, had optimized clinical grade assay that he uses in the clinical lab so that it's really high quality.

And then he used this method to determine how effective many or which one of the 576 tumor actually expressed the receptor or not.

And then so that we reported these data in the last manuscript.

Because GLP-1 receptor expression wasn't evenly distributed across net types, some were much more likely to express the receptor than others.

Poe Hein Eer and her colleagues set out to investigate.

In our latest study, we profiled 576 tumors from patients to see, and these are actually from 13 different neuroendocrine tumor types.

and different neuroendocrine carcinoma types as well.

So there are 13 in category in total, and there are 576 tumor in this study.

And then so our pathologist, Dr. Andrew Bellisi, had optimized clinical grade assay that he uses in the clinical lab so that it's really high quality.

And then he used this method to determine how effective many or which one of the 576 tumor actually expressed the receptor or not.

And then so that we reported these data in the last manuscript.

Because GLP-1 receptor expression wasn't evenly distributed across net types, some were much more likely to express the receptor than others.